{"filings":[{"id":2033478,"accession_number":"0001193125-26-331516","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2026-08-04T11:02:52+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Larimar Q2 net loss $32.8M; nomlabofusp BLA rolling submission underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $32.8M ($0.30/sh) vs $26.2M ($0.41/sh) in Q2 2025; cash $156.3M, runway into Q3 2027.","Open-label study: 43 participants dosed; 82% achieved skin FXN above asymptomatic carriers at 6 months, 100% at 1 year.","mFARS benefit of 2.6 points at 1 year vs natural history; no withdrawals from injection site reactions.","Rolling BLA for accelerated approval started; completion expected 2H 2026; confirmatory Phase 3 first patient dosing expected Q3 2026.","Targeting mid-2027 launch if approved; FDA agreed FXN as surrogate endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1314876,"accession_number":"0001193125-26-286780","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2026-06-29T10:33:36+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar submits BLA module for nomlabofusp accelerated approval; positive open-label data in Friedreich's ataxia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted first module of rolling BLA to FDA for accelerated approval of nomlabofusp; FDA confirmed existing data appears sufficient.","Open-label study: 100% (9/9) of participants achieved skin FXN levels >50% of healthy volunteer mean at 1 year.","Clinical outcomes improved vs natural history: mean 1.0-point mFARS improvement vs 1.6-point worsening at 1 year.","Safety: anaphylaxis in 10/43 patients; 9 had prior nomlabofusp exposure, 1 no prior; all recovered.","First patient in confirmatory Phase 3 expected Q3 2026; targeting mid-2027 launch if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":527556,"accession_number":"0001193125-26-230852","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2026-05-19T20:27:34+00:00","items":["5.07"],"status":"ready","headline":"Larimar shareholders approve increase in authorized shares to 215M; reelect three directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment increasing authorized common shares from 115M to 215M (89.7M for, 1.05M against).","Three Class III directors (Frank Thomas, Carole Ben-Maimon, Joseph Truitt) reelected with >66M votes each.","Advisory vote on executive compensation passed (73.8M for, 1.5M against); one-year frequency selected.","Ratification of PricewaterhouseCoopers as independent auditor for FY 2026 (90.8M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77441,"accession_number":"0001193125-26-222746","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2026-05-14T11:02:34+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Larimar plans rolling BLA for nomlabofusp in June 2026; Q1 net loss $29.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss Q1 2026 $29.6M ($0.31/sh) vs Q1 2025 $29.3M ($0.46/sh). Cash $200.4M.","Intends to initiate rolling BLA seeking accelerated approval June 2026; CMC module H2 2026.","Topline open-label study data expected Q2 2026; Phase 3 first patient dose mid-2026.","Breakthrough Therapy Designation granted Feb 2026. Skin frataxin as surrogate endpoint supported by published data.","Feb 2026 $115M public offering extended cash runway into Q2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103360,"accession_number":"0001193125-26-115119","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Larimar reports Q4 net loss $62.5M; BLA for nomlabofusp on track for June 2026 submission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025 $62.5M ($0.73/sh) vs $28.8M ($0.45/sh) in Q4 2024; R&D expenses rose to $59.4M.","Full-year 2025 net loss $165.7M ($2.27/sh) vs $80.6M ($1.32/sh) in 2024.","Cash & equivalents $136.9M at Dec 31, 2025; pro forma $244.5M after Feb 2026 $107.6M offering, runway into Q2 2027.","FDA granted Breakthrough Therapy Designation for nomlabofusp in FA; FDA alignment on FXN as surrogate endpoint.","Phase 3 confirmatory study screening to start Q2 2026; topline open-label data expected Q2 2026; BLA submission June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103359,"accession_number":"0001193125-26-098493","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar Therapeutics posts updated corporate presentation; no material news disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made updated corporate slide presentation available on its website on March 9, 2026.","Presentation will be used in meetings with investors and analysts.","No specific financial results, guidance, or material events were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103358,"accession_number":"0001193125-26-077646","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Larimar Therapeutics prices 20M share public offering at $5.00 per share; underwriters exercise over-allotment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 20,000,000 shares plus 3,000,000 over-allotment shares at $5.00 per share.","Net proceeds after underwriting discounts and expenses expected to be approx. $107.6M.","Underwriters include J.P. Morgan, Guggenheim, LifeSci Capital, William Blair, and others.","Offering expected to close on February 27, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103357,"accession_number":"0001193125-26-065186","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar Therapeutics receives FDA Breakthrough Therapy Designation for nomlabofusp in Friedreich's ataxia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation for nomlabofusp for adults and children with Friedreich's ataxia.","FDA aligned on using skin FXN as a surrogate endpoint to support BLA seeking accelerated approval.","Planned BLA submission remains on track for June 2026; topline open-label data expected Q2 2026.","Global confirmatory Phase 3 study to initiate Q2 2026; first patient dosing targeted mid-2026.","U.S. launch targeted for first-half 2027, if approved; estimated 5,000 U.S. patients with FA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103356,"accession_number":"0001193125-26-018664","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["3.02","5.03","9.01"],"status":"ready","headline":"Larimar Therapeutics exchanges 2.5M common shares for Series A convertible preferred with Blue Owl","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Blue Owl Healthcare exchanged 2,500,000 common shares for 250,000 Series A convertible preferred shares (10:1 conversion ratio).","Series A preferred has no voting rights except as required by law and ranks pari passu with common on liquidation.","Certificate of Amendment increased authorized Series A preferred from 250,000 to 500,000 shares.","Exchange expected to close Jan 23, 2026, exempt from registration under Section 3(a)(9) of the Securities Act.","Preferred shares are convertible into up to 2.5M common shares, subject to beneficial ownership limitations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103355,"accession_number":"0001193125-26-010409","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Larimar Therapeutics reports preliminary cash position of $136.9M as of Dec 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and marketable securities of $136.9M as of Dec 31, 2025, unaudited.","Amount is subject to completion of quarter-end and year-end financial close procedures.","Full year 2025 financial results will be included in the upcoming Form 10-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119605,"accession_number":"0001193125-25-321738","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["3.02","5.03","9.01"],"status":"ready","headline":"Larimar exchanges 2.5M common shares for 250K convertible preferred with Blue Owl","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Blue Owl Healthcare exchanged 2,500,000 common shares for 250,000 Series A convertible preferred shares.","Each preferred share converts into 10 common shares (2.5M total); conversion blocker set at 9.99%.","Preferred stock has no voting rights except on amendments; ranks pari passu with common on liquidation.","Exchange executed under Section 3(a)(9) exemption; no commissions paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119604,"accession_number":"0001193125-25-273217","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar posts corporate deck; no material new facts in filed excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Larimar posted an updated corporate presentation on its website on November 10, 2025.","Presentation is intended for investor and analyst meetings; no specific updates provided.","Filed excerpt contains only the title slide; substantive content not available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119603,"accession_number":"0001193125-25-265702","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Larimar Therapeutics Q3 2025: Net loss $47.7M, nomlabofusp shows 100% FXN level in OL study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 2025 was $47.7M ($0.61 per share) vs $15.5M in Q3 2024, with R&D expenses up to $44.9M.","100% of participants (n=10) achieved skin FXN levels similar to asymptomatic carriers after 6 months of daily nomlabofusp in open-label study.","Anaphylaxis occurred in 7 of 65 total participants; new modified starting dose regimen implemented to mitigate risk, agreed with FDA.","BLA submission seeking accelerated approval targeted for Q2 2026, with $175.4M cash runway into Q4 2026.","Consistent directional improvement across mFARS, FARS-ADL, 9-HPT, and MFIS after 1 year versus worsening in FACOMS reference."],"consensus_eps_estimate":-0.4121,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119602,"accession_number":"0001193125-25-237998","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar posts updated corporate presentation; no financial or clinical data in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["The 8-K filed on Oct 14, 2025, indicates an updated slide deck was posted on the company website.","No numerical data, pipeline updates, or financial guidance were included in the filing text.","The slide presentation (Exhibit 99.1) is referenced but its content is not available for review.","Investors are directed to the company website for the full presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136182,"accession_number":"0001193125-25-221538","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar reports positive nomlabofusp data; all 6-month patients reach carrier-level FXN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["10/10 participants at 6 months achieved skin FXN >50% of healthy volunteer median (asymptomatic carrier levels).","Directional improvement in mFARS, FARS-ADL, 9-HPT, MFIS vs worsening in natural history cohort after 1 year.","Anaphylaxis occurred in 7 participants (all within first 6 weeks); starting dose regimen modified; FDA agreed.","BLA submission seeking accelerated approval for nomlabofusp expected in Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136181,"accession_number":"0000950170-25-108409","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Larimar Therapeutics reports Q2 2025 net loss $26.2M; BLA for nomlabofusp on track for Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.2M ($0.41/share) vs $21.6M ($0.34) in Q2 2024; R&D expenses $23.4M, up from $19.7M.","Cash, equivalents, marketable securities $138.5M at June 30; pro forma $203.6M incl. $65.1M July offering; runway into Q4 2026.","FDA recommends safety database: 30+ participants on 50 mg for 6 months, subset of 10 for 1 year.","Initial 50 mg open-label and adolescent PK run-in data expected September 2025.","Global Phase 3 sites identified in US, EU, UK, Canada, Australia; patient recruitment to begin later 2025."],"consensus_eps_estimate":-0.4898,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136180,"accession_number":"0001193125-25-169818","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Larimar Therapeutics prices $64.4M common stock offering at $3.20 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 18,750,000 shares of common stock at $3.20; underwriters' over-allotment of 2,812,500 shares exercised in full.","Net proceeds expected approximately $64.4 million after underwriting discounts and expenses.","Joint book-running managers: Leerink Partners, Guggenheim Securities, Truist Securities, William Blair.","Offering expected to close July 31, 2025, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136179,"accession_number":"0001193125-25-168096","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Larimar Therapeutics reports preliminary cash balance of $138.5M as of June 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities of $138.5M as of June 30, 2025.","Disclosed in a preliminary prospectus supplement filed under Rule 424(b)(5) on July 29, 2025.","Financial close for Q2 2025 not complete; amount subject to change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153248,"accession_number":"0000950170-25-089074","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar posts updated corporate presentation for investor meetings","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted updated slide presentation on June 23, 2025 for use in meetings with investors and analysts.","No financial results, guidance changes, or material business events were disclosed in the filing.","Presentation covers general corporate overview; specific new content could not be extracted from the exhibit.","LRMR trades on Nasdaq; no material updates to pipeline or financial position reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153247,"accession_number":"0000950170-25-088704","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar gets FDA safety database guidance; nomlabofusp BLA submission planned for Q2 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA recommends safety database of ≥30 participants with 6-month continuous exposure (≥10 with 1-year), majority on 50 mg dose.","BLA submission for accelerated approval now targeted for Q2 2026 to include recommended safety data.","OLE data expected September 2025 from 30-40 participants, including those on the 50 mg dose.","Adolescent PK run-in data also expected September 2025 from 14 participants (some placebo).","FDA open to skin frataxin as reasonably likely surrogate endpoint; global Phase 3 study activities ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153246,"accession_number":"0000950170-25-070287","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Larimar Therapeutics holds 2025 Annual Meeting; all proposals pass","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Thomas E. Hamilton elected Class II director with 46.5M votes for, 4.3M withheld.","Advisory say-on-pay approved: 49.2M for, 1.4M against, 0.2M abstain.","Ratification of PricewaterhouseCoopers as auditor for 2025: 57.7M for, 10.9K against.","No other material proposals; all votes passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153245,"accession_number":"0000950170-25-063125","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar posts updated corporate presentation; no material new data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated slide deck dated May 5, 2025 posted on company website.","Presentation intended for use in meetings with investors, analysts, and other parties.","Filing does not disclose any new financial, clinical, or operational information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153244,"accession_number":"0000950170-25-060563","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Larimar Q1 net loss $29.3M; FDA open to accelerated approval using skin FXN as surrogate endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.3M ($0.46 per share) vs $14.7M ($0.27) YoY; R&D spend rose to $26.6M on manufacturing and Phase 3 prep.","Cash, equivalents and marketable securities $157.5M as of March 31, 2025; runway into Q2 2026.","FDA agreed to consider skin FXN concentration as reasonably likely surrogate endpoint for accelerated approval.","BLA submission planned by year-end 2025; global Phase 3 study to begin mid-2025 with U.S. and international sites.","Adolescent PK run-in dosing completed; 50 mg OLE and adolescent data expected in September 2025 program update."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172018,"accession_number":"0000950170-25-043487","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Larimar reports FDA open to FXN as surrogate endpoint; BLA submission on track for end-2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA considers skin FXN concentration reasonably likely surrogate endpoint for accelerated approval of nomlabofusp in Friedreich's ataxia.","BLA submission for accelerated approval targeted by year-end 2025; global Phase 3 study to initiate mid-2025.","Net loss of $28.8M in Q4 2024 ($0.45/share) vs. $13.0M ($0.30/share) in Q4 2023; R&D expenses rose to $26.7M.","Cash and equivalents $183.5M as of Dec 31, 2024; projected runway into Q2 2026.","OLE study amended to include premedication after anaphylaxis deemed adverse drug reaction; 50 mg data expected Sept 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172017,"accession_number":"0000950170-25-009196","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Larimar grants performance-based PSUs to four top executives","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Carole Ben-Maimon receives 100,000 PSUs tied to regulatory milestones.","CFO Michael Celano gets 50,000 PSUs; CDO Gopi Shankar and CMO Russell Clayton each get 25,000.","PSUs vest 50% upon milestone achievement determination and 50% one year later.","All grants made Jan 22, 2025 under the 2020 Equity Incentive Plan; forfeiture upon termination before vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172016,"accession_number":"0000950170-25-003794","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar Therapeutics posts updated corporate presentation on website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed an 8-K announcing an updated slide presentation posted on January 10, 2025.","Presentation will be used in meetings with investors, analysts, and other parties.","No specific new financial or clinical data disclosed in the filing or attached exhibit text.","Exhibit 99.1 text was not provided; only a fragment referencing the deck title is available.","Update appears routine with no material new information for investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189007,"accession_number":"0000950170-24-136384","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar reports positive OLE data: FXN up to 30% of healthy in buccal cells at Day 90; BLA filing targeted 2H 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean change from baseline of 1.32 pg/μg in buccal cells and 9.28 pg/μg in skin cells at Day 90.","Tissue FXN increased from 15% to 30% of healthy volunteers in buccal cells and 16% to 72% in skin cells.","Daily 25 mg nomlabofusp generally well tolerated; two SAEs resolved within 24 hours; 50 mg dose escalation initiated.","BLA submission for potential accelerated approval targeted for 2H 2025; cash runway of $203.7M into Q2 2026.","Early trends towards improvement in mFARS, ADL, and other clinical outcomes observed at Day 90."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189006,"accession_number":"0000950170-24-127768","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar Therapeutics posts corporate slide presentation; no material facts visible from truncated exhibit","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed 8-K on Nov 18, 2024, attaching a corporate presentation (Exhibit 99.1).","Presentation content not fully available; only header 'November 2024 Larimar Therapeutics Corporate Deck' shown.","Presentation will be used in investor and analyst meetings, but no specific updates disclosed in filing.","Unable to extract numerical targets, pipeline milestones, or financial guidance from the provided text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189005,"accession_number":"0000950170-24-118586","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Larimar reports Q3 2024 net loss of $15.5M; cash $203.7M, BLA target 2H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.5M ($0.24 per share) vs $9.1M loss ($0.21 per share) in Q3 2023.","Cash, cash equivalents and marketable securities $203.7M as of Sep 30, 2024; projected runway into 2026.","Nomlabofusp program update in mid-Dec with safety, PK, frataxin data from 25 mg daily OLE study.","PK run-in study in adolescents on track by year-end 2024; global confirmatory study planned mid-2025.","BLA submission for nomlabofusp targeted for 2H 2025 to support potential accelerated approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205483,"accession_number":"0000950170-24-092265","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Larimar Q2 net loss $21.6M; cash $226.1M; OLE interim data Q4; FDA START program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.6M ($0.34/sh) vs $8.4M loss in Q2 2023; R&D spend $19.7M up from $5.9M on manufacturing.","Cash, equivalents and marketable securities $226.1M at June 30; projected runway into 2026.","Open-label extension study all 7 sites activated; interim data planned Q4 2024.","FDA selected nomlabofusp for START pilot to accelerate development; BLA submission targeted 2H 2025.","Planning PK run-in study in adolescents by year-end 2024; global confirmatory study by mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222415,"accession_number":"0000950170-24-071056","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar posts updated corporate presentation; no specific changes disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted updated slide presentation on its website on June 10, 2024.","Presentation will be used in meetings with investors and analysts.","No financial results or material developments included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222414,"accession_number":"0000950170-24-067306","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Larimar Therapeutics shareholders elect Class I directors, approve all proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jonathan Leff and Jeffrey Sherman re-elected as Class I directors with ~40.7M and ~51.1M votes for, respectively.","Advisory vote on executive compensation approved with ~48.8M for, ~2.4M against.","Ratification of PricewaterhouseCoopers LLP as auditor for FY2024 approved with ~59.6M for.","Amendment to certificate of incorporation regarding officer exculpation approved with ~50.9M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222413,"accession_number":"0000950170-24-066571","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA selects Larimar's nomlabofusp for START pilot program to accelerate FA development","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA selects nomlabofusp for START pilot program based on potential clinical benefit and program readiness.","Nomlabofusp is one of three CDER programs selected; BLA submission target remains 2H 2025.","START program offers enhanced ad-hoc FDA communication to expedite pivotal studies and BLA preparation.","Interim data from ongoing open-label extension study expected in Q4 2024.","Nomlabofusp aims to increase frataxin levels, addressing root cause of Friedreich's ataxia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222412,"accession_number":"0000950170-24-062387","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA removes partial clinical hold on Larimar's nomlabofusp for Friedreich's Ataxia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared Phase 2 data review; nomlabofusp generally well-tolerated with dose-dependent frataxin increases.","OLE study continues at 25 mg; dose escalation to 50 mg planned after further frataxin PD characterization.","Interim OLE data expected Q4 2024; BLA submission targeted for 2H 2025.","In 50 mg cohort, all evaluable patients achieved skin frataxin >33% of healthy volunteer average at Day 14."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222411,"accession_number":"0000950170-24-056248","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Larimar Q1 net loss $14.7M; cash $239M; nomlabofusp Phase 2 positive; OLE dosed; BLA target 2H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.7M ($0.27/shr) vs $6.5M in Q1 2023; R&D expenses rose to $12.9M on manufacturing and clinical costs.","Cash, equivalents and marketable securities $239M after $161.8M public offering; runway extended into 2026.","Positive Phase 2 dose exploration: nomlabofusp generally well-tolerated, dose-dependent frataxin increases in skin and buccal cells.","First patient dosed in open-label extension (OLE) study of 25 mg daily; interim data on track for Q4 2024.","BLA submission targeted second half 2025; FDA discussions underway for accelerated approval using frataxin as surrogate endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241934,"accession_number":"0000950170-24-031467","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Larimar reports positive Phase 2 data for nomlabofusp; $161.6M financing extends runway into 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 dose exploration study met endpoints: dose-dependent frataxin increases in skin and buccal cells; 50 mg cohort saw levels >33% of healthy volunteers in all patients at Day 14.","FDA discussions initiated for using tissue frataxin as surrogate endpoint for accelerated approval; BLA submission targeted for 2H 2025.","Open-label extension (OLE) study of 25 mg daily nomlabofusp dosed first patient in March 2024; interim data expected Q4 2024.","Raised $161.6M net proceeds from public offering in Feb 2024; cash position $86.8M at Dec 31, 2023 before offering.","Q4 2023 net loss $13.0M ($0.30/share) vs $9.4M ($0.21/share) in Q4 2022; R&D expenses $10.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241933,"accession_number":"0000950170-24-029236","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar doses first patient in open-label extension study of nomlabofusp for Friedreich's ataxia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in OLE evaluating 25 mg daily subcutaneous nomlabofusp for Friedreich's ataxia.","OLE to assess long-term safety, pharmacokinetics, and tissue frataxin levels; initial data expected Q4 2024.","Frataxin data from OLE and prior studies intended to support BLA for accelerated approval targeted H2 2025.","Nomlabofusp remains under partial clinical hold; 50 mg cohort data will be submitted to FDA for dose escalation review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241932,"accession_number":"0001193125-24-038473","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Larimar Therapeutics closes $161.8M public offering of 19.7M shares at $8.74","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 17,162,472 shares plus 2,574,370 option shares exercised immediately.","Net proceeds ~$161.8M after underwriting discounts and estimated expenses.","Joint bookrunners: Leerink Partners, Citigroup, Guggenheim Securities.","All shares sold by company; offering closed February 16, 2024.","Proceeds will support clinical development of nomlabofusp (CTI-1601) and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241931,"accession_number":"0000950170-24-014919","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Larimar Therapeutics terminates at-the-market equity facility with Guggenheim; no shares ever sold","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Terminated Sales Agreement with Guggenheim Securities effective Feb 13, 2024.","Agreement permitted up to $50M in at-the-market common stock offerings.","No shares of common stock were ever sold under the agreement.","Original agreement date was November 10, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241930,"accession_number":"0000950170-24-013563","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Larimar reports positive Phase 2 nomlabofusp data; frataxin dose response up to 5.57 pg/µg in skin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["50 mg cohort: median FXN increase in skin 5.57 pg/µg at day 14; all patients reached >33% healthy volunteer level.","25 mg cohort: median FXN increase in skin 2.81 pg/µg; one allergic AE resolved; 18 of 19 completed.","Cash $86.8M as of Dec 31, 2023; expected runway into Q1 2025.","OLE initiated Jan 2024 starting 25 mg daily; interim data expected Q4 2024.","FDA discussions ongoing for accelerated approval using FXN as surrogate; BLA submission targeted 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259361,"accession_number":"0000950170-23-063347","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Larimar completes Phase 2 50mg cohort enrollment; top-line data now Q1 2024; cash to Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment and dosing of 50 mg cohort in Phase 2 FA trial; no serious adverse events observed (blinded).","Top-line safety, PK, and frataxin data now expected in Q1 2024, refined from H1 2024.","Open-label extension trial with 25 mg daily nomlabofusp on track for Q1 2024; interim data expected Q4 2024.","Cash, equivalents, and marketable securities of $95.6M as of Sep 30, 2023; projected runway into Q1 2025.","Q3 2023 net loss $9.1M ($0.21/share) vs $8.3M ($0.37/share) in Q3 2022; R&D expenses up to $6.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259360,"accession_number":"0001193125-23-249962","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Larimar Therapeutics appoints Dr. Jeffrey W. Sherman to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 5 to 6 members; Dr. Sherman appointed as Class I director through 2024 annual meeting.","Dr. Sherman is EVP and Chief Medical Officer of Horizon Therapeutics, with extensive biopharma leadership experience.","Received option to purchase 16,600 shares of common stock, vesting monthly over 36 months.","Appointed to Nominating and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276636,"accession_number":"0000950170-23-042070","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar Therapeutics posts updated investor presentation; no financial results disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted an updated slide presentation on its website on August 14, 2023 for use in investor meetings.","No new financial guidance, clinical data, or material business developments were disclosed in the 8-K.","The presentation is filed as Exhibit 99.1 but its full content is not available in the provided text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276635,"accession_number":"0000950170-23-040946","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Larimar Therapeutics Q2 net loss $8.4M; FDA clears 50 mg cohort and OLE trial for CTI-1601 in FA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.4M (-$0.19/share) vs $8.7M in Q2 2022; cash $104.2M, runway into Q4 2024.","FDA cleared initiation of 50 mg cohort in Phase 2 FA trial and Open-Label Extension after review of 25 mg data.","Top-line data from 25 mg cohort showed CTI-1601 was well-tolerated and increased frataxin levels from baseline.","New CMO appointed: Russell Clayton, DO, replaces retired Nancy Ruiz.","Expect top-line 50 mg data in 1H 2024; OLE interim data in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276634,"accession_number":"0000950170-23-034217","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clears Larimar's Phase 2 CTI-1601 trial to proceed to 50 mg cohort and OLE trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared Phase 2 dose exploration trial to proceed to 50 mg cohort; dosed daily for 14 days then every other day to day 28.","FDA also cleared initiation of open label extension (OLE) trial with 25 mg daily CTI-1601; enrollment expected Q1 2024, interim data Q4 2024.","Top-line safety, PK, and frataxin data from the 50 mg cohort expected in first half of 2024.","Clearance follows FDA review of unblinded data from completed 25 mg cohort (n=13) showing frataxin increases vs placebo.","Further dose escalation and additional U.S. trials remain under partial clinical hold pending FDA review of 50 mg cohort results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276633,"accession_number":"0000950170-23-033196","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar Therapeutics appoints Russell Clayton as CMO, 180K stock option inducement grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Russell 'Rusty' Clayton appointed Chief Medical Officer effective July 17, 2023, succeeding Nancy M. Ruiz (retiring).","Dr. Clayton previously served as Principal at Aeremedea, LLC and as advisor to Larimar for 5 years.","Inducement award of 180,000 stock options granted under Nasdaq Listing Rule 5635(c)(4), vesting over 4 years.","Dr. Clayton brings ~20 years of rare disease experience, including roles at Alcresta Therapeutics and Merck."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294398,"accession_number":"0000950170-23-025691","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Larimar Therapeutics posts updated corporate presentation for investor meetings","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated slide presentation posted on company website on June 1, 2023.","No specific changes or material updates disclosed in the filing or attached exhibit.","Presentation intended for use in meetings with investors and analysts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294397,"accession_number":"0000950170-23-021953","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Larimar Phase 2 trial shows frataxin increases in skin and buccal cells; Q1 net loss $6.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median placebo-adjusted frataxin increase from baseline: 3.5 pg/µg in skin, 0.9 pg/µg in buccal cells at day 14.","CTI-1601 generally well tolerated; one severe allergic reaction led to withdrawal; 8 of 9 completed the cohort.","Data submitted to FDA; meeting scheduled Q2 2023; program update expected Q3 2023.","Q1 2023 net loss $6.5M ($0.15/diluted share) vs $8.9M ($0.49) in Q1 2022; cash $111.5M as of March 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294396,"accession_number":"0000950170-23-021747","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Larimar Therapeutics stockholders elect three Class III directors at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Frank Thomas, Carole S. Ben-Maimon, and Joseph Truitt as Class III directors until 2026.","Advisory say-on-pay vote approved with 35.5M votes for, 337.9K against.","Ratified PricewaterhouseCoopers as independent auditor for FY2023 (40.8M for).","Broker non-votes of ~4.9M on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294395,"accession_number":"0001193125-23-093965","cik":1374690,"company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","form_type":"8-K","filed_at":"2023-04-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Peter Barrett to resign from Larimar Therapeutics Board effective May 9, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Barrett, Ph.D., resigned from the Board, effective May 9, 2023, the date of the 2023 Annual Meeting.","Dr. Barrett's resignation did not result from any disagreement with the Company on operations, policies, or practices.","The Company expressed gratitude for Dr. Barrett's distinguished service and lasting contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":360993195.9659091,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-06T23:59:59+00:00|294395"}